Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29714531 | 1.00 | TLR7 (0.55) | TLR7TLR8 | |
| SCHEMBL5354266 | 0.92 | TLR7 (0.63) | TLR7 | |
| SCHEMBL5800432 | 0.91 | TLR7 (0.60) | TLR7TLR8 | |
| SCHEMBL6098681 | 0.91 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL13613796 | 0.91 | TLR7 (0.61) | TLR7TLR8 | |
| SCHEMBL5353603 | 0.91 | TLR7 (0.59) | TLR7TLR8 | |
| SCHEMBL30345323 | 0.91 | TLR8 (0.56) | TLR7TLR8 | |
| SCHEMBL5057099 | 0.91 | TLR8 (0.56) | TLR7TLR8 | |
| SCHEMBL6813136 | 0.90 | TLR7 (0.56) | TLR7TLR8 | |
| SCHEMBL6098376 | 0.89 | TLR7 (0.62) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | BIRDIE BIOPHARMACEUTICALS INC (KY) | 2023-12-07 | — | — | US | claimed |
| US-11633494-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| US-11633495-B2 | Compounds and compositions for immunotherapy | BIRDIE BIOPHARMACEUTICALS, INC. (KY) | 2023-04-25 | — | — | US | claimed |
| EP-4148069-A1 | ANTI-PD-L1 CONJUGATES FOR TREATING TUMORS | Birdie Biopharmaceuticals Inc. (KY) | 2023-03-15 | — | — | EP | claimed |
| CN-115554406-A | anti-CD 20 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2023-01-03 | — | — | CN | claimed |
| CN-115350279-A | anti-HER 2 combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-18 | — | — | CN | claimed |
| CN-115337402-A | Combination therapeutic compositions and combination therapeutic methods for treating cancer | 博笛生物科技有限公司 | 2022-11-15 | — | — | CN | claimed |
| CN-115252792-A | anti-EGFR combinations for the treatment of tumors | 博笛生物科技有限公司 | 2022-11-01 | — | — | CN | claimed |
| CN-114716555-A | Compounds and compositions for targeting EGFR expressing tumors | 博笛生物科技有限公司 | 2022-07-08 | — | — | CN | claimed |
| CN-114671954-A | Compounds and compositions targeting HER2 positive tumors | 博笛生物科技有限公司 | 2022-06-28 | — | — | CN | claimed |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | SHANGHAI BIRDIE BIOTECH, INC. (CN) | 2016-11-10 | — | — | US | claimed |
| US-7612083-B2 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-7049439-B2 | Immunomodulators for inducing cytokine biosynthesis; viricides; antitumor agents | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-05-23 | — | — | US | claimed |
| EP-1343784-B1 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS and pharmaceutical compositions comprising the same. | 3M INNOVATIVE PROPERTIES CO (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2005-10-20 | — | — | US | claimed |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-22 | — | — | US | claimed |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2004-04-15 | — | — | US | claimed |
| US-6656938-B2 | Inducing cytokine biosynthesis in animals, for the treatment of diseases, including viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-12-02 | — | — | US | claimed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | claimed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11633494-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
| US-20040072859-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-11633495-B2 | Compounds and compositions for immunotherapy | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20160324983-A1 | Compounds and Compositions for Immunotherapy | CD47, TP53, CD74 | TLR7 198/4885TLR8 159/4885 |
| US-20050234088-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 74/4885TLR8 257/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20040077678-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20230390410-A1 | COMPOUNDS AND COMPOSITIONS FOR IMMUNOTHERAPY | CD47, CD274, TP53 | TLR7 147/4885TLR8 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.